Ashvattha Therapeutics
- Biotech or pharma, therapeutic R&D
Ashvattha's nanomedicine technology targets activated macrophage and microglia. Phase 2 trial of subcutaneous migaldendrinib (MGB) in wAMD/DME and Phase 2 imaging study of 18F-flurimedrimer (18F-FMD) in neuroinflammation (ALS, MS, AD) are ongoing with interim results demonstrating clinical POC.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}